Catherine A. Lesjak
Known title: DirectorCIK: 0001256992
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
GE Aerospace Secures 600+ LEAP-1B Engine Deal, Eyes Q3 Earnings. GE Aerospace announced a memorandum of understanding with Turkish Airlines to purchase more than 600 LEAP‑1B engines, including spares. Analysts say aerospace and defense demand remains steady even as market sentiment softens, which could support the company’s earnings outlook. The company will report Q3 results shortly, and investors are watching how the new engine deal and broader demand trends play out.
Transaction History
| GEHC | ▲ Buy | Grant | 3,586 | $0 | 5/7/2026 | View on chart |
| GE | ▲ Buy | Grant | 678 | $0 | 5/5/2026 | View on chart |
| GEHC | ▲ Buy | Grant | 3,092 | $0 | 5/28/2025 | View on chart |
| GE | ▲ Buy | Grant | 968 | $0 | 5/6/2025 | View on chart |
| GEHC | ▲ Buy | Grant | 2,440 | $0 | 5/21/2024 | View on chart |
| GE | ▲ Buy | Grant | 1,165 | $0 | 5/7/2024 | View on chart |
| GEHC | ▲ Buy | Grant | 3,584 | $0 | 5/23/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
GEHC Secures CE Mark for MINItrace Magni Cyclotron
GE HealthCare (GEHC) has received CE approval for its MINItrace Magni cyclotron, expanding its PETtrace™ solid‑target platform to include copper‑64. The approval follows research showing its End‑tial Control software can reduce fresh gas flow in anesthesia settings. In addition, HeartBeam has joined a European consortium to develop at‑home ECG monitoring for early detection of acute coronary syndrome. These developments broaden GEHC’s product portfolio and support its investment narrative.
GEHC Secures CE Mark for MINItrace Magni Cyclotron. GE HealthCare (GEHC) has received CE approval for its MINItrace Magni cyclotron, expanding its PETtrace™ solid‑target platform to include copper‑64. The approval follows research showing its End‑tial Control software can reduce fresh gas flow in anesthesia settings. In addition, HeartBeam has joined a European consortium to develop at‑home ECG monitoring for early detection of acute coronary syndrome. These developments broaden GEHC’s product portfolio and support its investment narrative.